ARTICLE | Clinical News
Annamycin regulatory update
July 4, 2005 7:00 AM UTC
FDA granted Orphan Drug designation to annamycin, a second-generation anthracycline, to treat acute lymphoblastic leukemia (ALL). Annamycin completed a Phase I/IIa trial in refractory leukemia. ...